BC Extra | Feb 27, 2019
Clinical News

Novartis first partner in RWE collaboration for dermatology

PharmaSolutions Inc. announced on Wednesday that Novartis AG (NYSE:NOV; SIX:NOVN) will be the first biopharma collaborator in its TARGET-DERM real-world evidence generation program. TARGET-DERM will gather real world, de-identified patient-level data from electronic medical records...
BioCentury | Jul 21, 2017
Finance

Itching to invest

A growing strategic interest in pruritus underlies two series C rounds with multiple new investors that were announced the week of July 17. For Trevi Therapeutics Inc. , the $50.5 million round announced July 20 is...
BC Week In Review | Dec 30, 2016
Company News

Ziarco, Novartis deal

Novartis will acquire Ziarco for undisclosed financial terms. The deal gives the pharma ZPL-389 , an oral histamine H4 receptor ( HRH4 ; H4) antagonist. Ziarco previously said ZPL-389 missed the primary endpoint but significantly reduced Eczema...
BC Extra | Dec 16, 2016
Company News

Novartis gets eczema candidate in Ziarco takeout

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring Ziarco Group Ltd. (Canterbury, U.K.). The deal gives the pharma ZPL-389 , an oral histamine H4 receptor ( HRH4 ; H4) antagonist that has completed a Phase IIa trial to treat...
BC Week In Review | May 23, 2016
Clinical News

ZPL-389: Phase IIa data

Top-line data from a double-blind, European Phase IIa trial in 98 patients with moderate to severe atopic dermatitis showed that once-daily 30 mg oral ZPL-389 missed the primary endpoint of improving NRS for pruritus from...
BC Extra | May 17, 2016
Clinical News

Ziarco planning atopic dermatitis Phase IIb

Ziarco Group Ltd. (Canterbury, U.K.) said ZPL-389 missed the primary endpoint of pruritus as measured on a numerical rating scale vs. placebo in a 98-patient Phase IIa study to treat moderate to severe atopic dermatitis....
BC Week In Review | Feb 8, 2016
Clinical News

ZPL-389: Phase IIa started

Ziarco began a double-blind, placebo-controlled, international Phase IIa trial to evaluate 30 mg oral ZPL-389 once daily for 12 weeks in about 120 patients with moderate to severe psoriasis. Ziarco has exclusive, worldwide rights to...
BioCentury | Nov 17, 2014
Finance

Safety equals cash

Ziarco Group Ltd. 's combination of preclinical safety data and a better understanding of the mechanism of its lead asset led new investors to provide the dermatology play with enough cash to get two programs...
BC Extra | Nov 11, 2014
Financial News

Ziarco raises $33.1M series B

Ziarco Pharma Ltd. (Canterbury, U.K.) raised $33.1 million in a series B round led by New Enterprise Associates and Lundbeckfond Ventures. New investor Amgen Ventures and existing investors BVF Partners and Pfizer Venture Investments also...
BioCentury | Apr 8, 2013
Emerging Company Profile

Ziarco: Scratching the allergic itch

Ziarco Pharma Ltd. emerged last year from a shuttered Pfizer Inc. R&D site in Sandwich, U.K., with a quartet of allergy and inflammation assets that otherwise would have been shelved and forgotten. The biotech's lead...
Items per page:
1 - 10 of 14